Orfiril long 1000 mg Norveška - norveški - Statens legemiddelverk

orfiril long 1000 mg

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 1000 mg

Orfiril 150 mg Norveška - norveški - Statens legemiddelverk

orfiril 150 mg

desitin arzneimittel gmbh - natriumvalproat - enterotablett - 150 mg

Orfiril 600 mg Norveška - norveški - Statens legemiddelverk

orfiril 600 mg

desitin arzneimittel gmbh - natriumvalproat - enterotablett - 600 mg

Orfiril 100 mg/ ml Norveška - norveški - Statens legemiddelverk

orfiril 100 mg/ ml

desitin arzneimittel gmbh - natriumvalproat - injeksjonsvæske, oppløsning - 100 mg/ ml

Orfiril retard 300 mg Norveška - norveški - Statens legemiddelverk

orfiril retard 300 mg

desitin arzneimittel gmbh - natriumvalproat - depottablett - 300 mg

Spirix 25 mg Norveška - norveški - Statens legemiddelverk

spirix 25 mg

orifarm healthcare a/s - spironolakton - tablett - 25 mg

Spirix 50 mg Norveška - norveški - Statens legemiddelverk

spirix 50 mg

orifarm healthcare a/s - spironolakton - tablett - 50 mg

Spirix 100 mg Norveška - norveški - Statens legemiddelverk

spirix 100 mg

orifarm healthcare a/s - spironolakton - tablett - 100 mg

Phelinun Europska Unija - norveški - EMA (European Medicines Agency)

phelinun

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiske midler - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Methofill 10 mg Norveška - norveški - Statens legemiddelverk

methofill 10 mg

accord healthcare b.v. - metotreksat - injeksjonsvæske, oppløsning i ferdigfylt injektor - 10 mg